NCT05065021 2024-01-17
Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor
University Health Network, Toronto
Phase 2 Unknown
Clinical Trials
34 trialsNCT02584478 2023-11-08
AL3818
Advenchen Laboratories, LLC
Phase 3 Unknown
NCT04938583 2023-10-17
Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer
CanariaBio Inc.
Phase 1/2 Unknown
NCT04201561 2023-06-26
SELENIUM
Seoul National University Hospital
Phase 3 Unknown
NCT00326456 2023-03-27
MITO-2: A Study Comparing 2 Chemotherapy Regimens (Carboplatin/Liposomal Doxorubicin vs Carboplatin/Paclitaxel) in Patients With Ovarian Cancer
National Cancer Institute, Naples
Phase 3 Unknown
NCT00660842 2023-03-24
MITO-7
National Cancer Institute, Naples
Phase 3 Unknown
NCT01706120 2023-03-24
MITO16/MANGO-2
National Cancer Institute, Naples
Phase 4 Unknown
NCT01802749 2023-03-24
MITO16MANGO2b
National Cancer Institute, Naples
Phase 3 Unknown
NCT03410784 2023-03-24
MITO28MaNGOov4
National Cancer Institute, Naples
Phase 2 Unknown
NCT03321188 2023-02-06
Heated Intraperitoneal Chemotherapy in Primary Ovarian Cancer Patients
University of Kansas Medical Center
Phase 2 Unknown
NCT05158062 2022-04-26
Pembrolizumab and Bevacizumab With Chemotherapy Followed by Pembrolizumab, Bevacizumab and Olaparib in Recurrent Ovarian Cancer
Saitama Medical University International Medical Center
Phase 2 Unknown
NCT00954174 2021-09-30
Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer
GOG Foundation
Phase 3 Unknown
NCT04679064 2021-08-27
NItCHE-MITO33
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase 3 Unknown
NCT00652119 2020-08-19
Intraperitoneal Paclitaxel and Carboplatin With IV Avastin Therapy in Patients With Carcinomas of Mullerian Origin
Massachusetts General Hospital
Phase 1 Unknown
NCT03693248 2019-12-10
ROCOCO
Seoul National University Hospital
Phase 3 Unknown
NCT04000295 2019-10-08
Apatinib and Etoposide Capsule Versus Weekly Paclitaxel in Patients With Platinum Resistant Ovarian Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Unknown
NCT03818282 2019-02-26
OC-01
Huazhong University of Science and Technology
Phase 2 Unknown
NCT03763123 2018-12-04
A Phase 1b Study of Sevacizumab in Combination With Chemotherapy in Chinese Patients With Platinum-Resistant Recurrent Ovarian Cancer.
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 1 Unknown
NCT03539328 2018-05-29
MITO27
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Unknown
NCT01650376 2018-03-23
Phase Ib Study of Olaparib Plus Weekly Carboplatin and Paclitaxel in Relapsed Ovarian Cancer
Swedish Medical Center
Phase 1/2 Unknown
NCT03095001 2017-04-13
Intraperitoneal Chemotherapy Alone or in Combination With Bevacizumab for Ovarian Cancer With Peritoneal Adhesion
Chinese PLA General Hospital
Phase 2 Unknown
NCT02244502 2016-09-21
Safety, Feasibility and Effect of TTFields (200 kHz) Concomitant With Weekly Paclitaxel in Recurrent Ovarian Carcinoma (INNOVATE)
NovoCure Ltd.
Phase 1/2 Unknown
NCT02545010 2016-06-22
Phase I Low Dose WART in Combination With Weekly Paclitaxel for Platinum Resistant Ovarian Cancer
National University Hospital, Singapore
Phase 1 Unknown
NCT02435186 2015-05-06
p53 Gene in Treatment of Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer
Shenzhen SiBiono GeneTech Co.,Ltd
Phase 2 Unknown
NCT00003064 2014-01-06
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Persistent Epithelial Ovarian Cancer, Fallopian Tube, or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Phase 1/2 Unknown
NCT00017303 2013-11-06
Combination Chemotherapy Plus IM-862 in Treating Patients With Resected Stage III Ovarian Cancer or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00003733 2013-09-20
Sequential Chemotherapy in Treating Patients With Residual Disease Following Surgery for Stage IIB, Stage III, or Stage IV Ovarian Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00838656 2013-09-17
Two Different Schedules of Carboplatin, Paclitaxel, Gemcitabine, and Surgery in Treating Patients With Newly Diagnosed Stage IIIC or Stage IV Primary Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00964626 2013-08-26
Paclitaxel and Cisplatin as First-Line Treatment for Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00551122 2013-01-23
GemTIP
University of Southampton
Phase 1/2 Unknown
NCT01654146 2012-07-31
ICON8
Medical Research Council
Phase 3 Unknown
NCT01570582 2012-04-04
A Phase IIclinical Trial of Carboplatin and Paclitaxel or Carboplatin and Gemcitabine in Platinum-sensitive, Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
Korean Gynecologic Oncology Group
Phase 2 Unknown
NCT00003160 2011-04-20
Weekly Infusions of Paclitaxel in Treating Women With Stage III or Stage IV Ovarian Cancer Refractory to Paclitaxel and Platinum
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00772798 2008-10-15
A Phase I/II Study of Paclitaxel Plus Carboplatin Plus Vorinostat in Recurrent Ovarian Cancer
Herlev Hospital
Phase 2 Unknown